Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that exceeded 70% in a phase II study, but failed to meet prespecified ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments in bladder cancer frequently have made news over the past 12 months. The ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in ...

Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC). EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as ...